A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Ruxotemitide (Primary)
- Indications Basal cell cancer
- Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
- Sponsors Verrica Pharmaceuticals
- 30 May 2024 According to a Lytix Biopharma media release, preliminary phase II top-line data expected Q2 2024.
- 13 May 2024 According to a Verrica Pharmaceuticals media release, company expects to announce phase 2 results in this quarter.
- 29 Feb 2024 According to a Lytix Biopharma media release, the entire study is set to be completed in H1 2024.